Bone Cancer
Also known as: Metastasis, Metastases, Metastatic, Mets
Methodology & AI Transparency ⓘ
Bone Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cancer that starts in a bone is uncommon.
- 2 Real-world patient consensus: Clinical coding for Bone Cancer uses ICD-10 C79.51 across Cancer & Oncology specialty care.
- 3 Typical cash cost range: Differential triage of Bone Cancer (C79.51) utilizes multidisciplinary tumor-board planning in Bone Cancer (C79.51: (surgery).
- 4 Top reported side effects / signs: Longitudinal Bone Cancer monitoring tracks Pathology / Molecular in Bone Cancer (C79.51: Genomic Staging) toward Guideline-concordant surveillance (C79.51).
Ask our AI Specialists anything about Bone Cancer
What Is Bone Cancer?
Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy.
Pathophysiology, Underlying Causes & Clinical Presentation
In Bone Cancer (C79.51), physiological disruption stems from microenvironment inflammation [Bone Cancer C79.51], Cross-referenced with NIH MeSH (Bone Neoplasms), informing Cancer, Oncology & Supportive Care protocols that track Complete Blood Count in Bone Cancer (C79.51: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (C79.51)).
Common Symptoms & Clinical Signs
- • Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm
- • Chondrosarcoma - starts in cartilage, usually after age 40
- • Presentation of Bone Cancer (C79.51): unexplained bleeding, chronic in Bone Cancer (C79.51: hoarseness/cough, or progressive)
- • Secondary Bone Cancer clinical sign: abnormality detected early in Bone Cancer (C79.51: on age-appropriate screening)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Bone Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C79.51 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Bone Cancer (C79.51: Genomic Staging) | Guideline-concordant surveillance (C79.51) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Bone Cancer (C79.51: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C79.51) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Bone Cancer (C79.51: Organ Function Panel) | Preserved renal/hepatic clearance (C79.51) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bone Cancer
Treatment selection for Bone Cancer depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bone Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Testosterone supplementation and bone: What a 3,103-Participant Study Found TRT is able to inhibit bone resorption and increase bone mass, particularly at the lumbar spine level and when the duration is long enough to allow the anabolic effect of T and estrogens on bone metabolism to take place. Journal of endocrinological investigation • 2022-05-15 • Meta-Analysis | N = 3,103 | 99/100 | PMID 35041193 ↗ |
| New Insights on Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone: What a 4,914-Participant Study Found High heterogeneity and diverse follow-up durations among studies were evident, which obscures the validity of the results. International journal of molecular sciences • 2024-07-22 • Meta-Analysis | N = 4,914 | 99/100 | PMID 39063229 ↗ |
| New Insights on Contrasting Bone Profiles in PCOS Are Related to: What a 1,822-Participant Study Found The findings of this study alert for a low bone mass, low bone formation, and increased bone resorption PCOS with a BMI <27 kg/m2. The Journal of clinical endocrinology and metabolism • 2024-09-16 • Meta-Analysis | N = 1,822 | 94/100 | PMID 38739756 ↗ |
| New Insights on Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A: What a 447-Participant Study Found We did not find sufficient evidence to suggest any detrimental effect of pelvic XRT on the treatment effect from denosumab on percent BMD change, with only an approximately 5% incidence of clinical fractures. International journal of radiation oncology, biology, physics • 2024-05-01 • Phase III Randomized Trial | N = 447 | 93/100 | PMID 37924987 ↗ |
| New Insights on Benefits and safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients: What a 357-Participant Study Found Denosumab biosimilar QL1206 had promising efficacy, tolerable safety, and how the body absorbs the medicine equivalent to denosumab and could benefit patients with bone metastases from solid tumors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy • 2023-03-15 • Phase III Randomized Trial | N = 357 | 93/100 | PMID 36802320 ↗ |
Bone Cancer Patient Community & “People Like Me” Threads
Filter Bone Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.